A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.
We previously described different cytotoxic T lymphocyte (CTL) clones isolated from the blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. These CTL clones recognized at least 2 distinct antigens on the melanoma cells. Here, we show that one of them consists of a peptide derived from tyrosinase and presented by HLA-B35. The peptide is 9 amino acids long and has the sequence LPSSADVEF. It can be presented by the 2 major B35 allelic subtypes, B*3501 and B*3503. As HLA-B35 is one of the most frequent HLA-B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide-based immunotherapy of melanoma.
Morel
S
S
Ludwig Institute for Cancer Research, Université Catholique de Louvain, Brussels, Belgium.
Ooms
A
A
Van Pel
A
A
Wölfel
T
T
Brichard
V G
VG
van der Bruggen
P
P
Van den Eynde
B J
BJ
Degiovanni
G
G
D000483:Alleles; D000595:Amino Acid Sequence; D000818:Animals; D001402:B-Lymphocytes; D019556:COS Cells; D002461:Cell Line, Transformed; D003602:Cytotoxicity, Immunologic; D015797:HLA-B35 Antigen / Q000235:genetics / Q000276:immunology*; D004854:Herpesvirus 4, Human; D006801:Humans; D008545:Melanoma / Q000276:immunology; D014442:Monophenol Monooxygenase / Q000737:chemistry / Q000276:immunology*; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured
D015797:HLA-B35 Antigen; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014442:Monophenol Monooxygenase